Skip to content Skip to sidebar Skip to footer

Newsletter

Healthcare Stocks

Invion (ASX:IVX): Using Photodynamic Therapy to fight cancer

Unless you're a professional dermatologist, you may not have ever heard of Photodynamic Therapy, let alone thought of it as an option to fight cancer as Invion (ASX:IVX) is doing. Invion may not appear to be an appealing investment at first glance, given its status as a 'penny stock' with a share price as a fraction…

ByNick SundichSeptember 9, 2024

Paradigm Biopharmaceuticals (ASX:PAR): An osteoarthritis solution that could hit the market within 3 years

If you thought the were plenty of treatments for osteoarthritis already, Paradigm Biopharmaceuticals (ASX:PAR) is a company that has something to say about that. You see, any ‘treatments’ that exist are only about addressing the pain or other symptoms rather than being a cure or remission. These treatments tend to need frequent administration or lose effectiveness…

ByNick SundichSeptember 6, 2024

Cann Group (ASX:CAN): Successfully producing GMP medicinal cannabis since 2017

Cann Group (ASX:CAN) is the first company in Australia that was issued a medicinal cannabis license, granted by the Australian Government's Office of Drug Control in March 2017. During this time, there have been various busts and booms in the cannabis sector, although there has been little hype since the aftermath of TGA's declassification of certain…

ByNick SundichSeptember 6, 2024

Percheron Therapeutics (ASX:PER): Releasing Phase II data by the end of CY24, and successful data could lead to a major re-rate

It has been less then a year since Antisense Therapeutics changed its name to Percheron Therapeutics (ASX:PER). It is common for biotech companies to change their name when they pivot to new indications and/or to new assets, but this was not the case with Percheron. It is still focused on Duchenne Muscular Dystrophy (DMD), a…

ByNick SundichSeptember 3, 2024

Proteomics International Laboratories (ASX:PIQ): It thinks its got a great DKD detection test, but do regulators agree?

Proteomics International Laboratories (ASX:PIQ) is one of the larger companies that will be presenting at next month's Life Sciences Conference. Capped at over $100m, its flagship product is PromarkerD, a predictive test for Diabetic Kidney Disease (DKD). Like all up and coming healthcare stocks, it has a great idea, but execution is the key. And…

ByNick SundichAugust 28, 2024

Here are 5 Monkeypox stocks to consider as the fight against the epidemic continues

Monkeypox stocks have enjoyed a good run in the last few weeks, with the World Health Organisation (WHO) classifying Monkeypox as a 'public health emergency of international concern'. Moneykpox is a virus that is spread through direct contact with infected liasons, bodily fluids or contaminated materials like bedding. It causes flu-like symptoms and skin blisters across…

ByNick SundichAugust 26, 2024

Here are 6 important milestones of ASX biotech companies other than clinical trial results and regulatory approval

The list of major milestones of ASX biotech companies is headed with clinical trial results, regulatory approval and commercialisation. However, clinical trials can take a long time, and there are no guarantees of success. And, as goes without saying, there won't be regulatory approval or commercialisation without results. As important as they are, there are other…

ByNick SundichAugust 23, 2024

Recce Pharmaceuticals investors are excited despite the market volatility – and there’s good reason

Recce Pharmaceuticals investors are amongst the few investors in ASX stocks that have a reason to smile right now. Their company has significantly outperformed the broader ASX, sitting in positive territory while the rest of the market has been volatile. Although there weren't any announcements out of Recce - other than the completion of its Share…

ByNick SundichAugust 22, 2024

Here are 4 economic indicators that impact stocks and investors must pay attention to

There are several economic indicators that impact stocks, both on the ASX and internationally. Whenever data is released, it can swing market indices in a particular direction, sometimes the opposite direction to where it had been heading earlier in the day. This is not only if the data changes from one period to another, but…

ByNick SundichAugust 19, 2024

As lower interest rates loom, here are 6 ASX stocks that will benefit from forthcoming rate cuts

Here 6 ASX stocks that will benefit from lower interest rates! AGL Energy (ASX:AGL) You might think AGL is on this list because people will have an easier time paying their electricity bills. Not quite for two reasons: First, Blind Freddy could tell you that, and Second, people are still paying their bills. We were…

ByNick SundichAugust 14, 2024

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

Invion (ASX:IVX): Using Photodynamic Therapy to fight cancer

Paradigm Biopharmaceuticals (ASX:PAR): An osteoarthritis solution that could hit the market within 3 years

Cann Group (ASX:CAN): Successfully producing GMP medicinal cannabis since 2017

Percheron Therapeutics (ASX:PER): Releasing Phase II data by the end of CY24, and successful data could lead to a major re-rate

Proteomics International Laboratories (ASX:PIQ): It thinks its got a great DKD detection test, but do regulators agree?

Here are 5 Monkeypox stocks to consider as the fight against the epidemic continues

Here are 6 important milestones of ASX biotech companies other than clinical trial results and regulatory approval

Recce Pharmaceuticals investors are excited despite the market volatility – and there’s good reason

Here are 4 economic indicators that impact stocks and investors must pay attention to

As lower interest rates loom, here are 6 ASX stocks that will benefit from forthcoming rate cuts

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Stocks in Spotlight

Add Your Heading Text Here